It has previously been reported that venetoclax monotherapy is effective in some, but not all, MM patients with t(11;14), and these patients have relatively high BCL‐2 gene expression compared with MCL‐1 and BCL‐XL [15]. This evidence concerns the gene BCL2L1 and Miyoshi myopathy.